| |
Hot Off the Press
PCSK9 Inhibitors and Cardiovascular Disease
Heralding a New Therapeutic Era
PCSK9 Forum Editors review the latest PCSK9 developments.
The first PCSK9 monoclonal antibody treatments were approved in Europe and the US earlier this year. Here, the Editors make the case for their use in severe familial hypercholesterolaemia (FH, inherited high cholesterol). Other high risk patients, including those who cannot tolerate statins, are also a priority.
Read the latest in the PCSK9 story here » Forward to colleagues »
Legacy Effects from PCSK9 Inhibitor Treatment?
Does profound LDL lowering with PCSK9 inhibition offer the possibility to alter the natural history of atherosclerotic vascular disease?
Professor Chris Packard poses the questions.
Read the editorial here » |
|
 |
In the News
Looking Back at AHA 2015
Roving PCSK9 Forum News Reporter Dr Peter Lansberg gives his views on the highlights.
Read the full report » |
 |
 |
Other News
Free e-book
Understanding PCSK9 inhibition
For healthcare professionals
Prepared by independent experts from PCSK9 Education and Research Forum.
Available free to registered members of the Forum.
Register and read online » Download now » |
 |
|
|
|
|
For the latest updates on conferences, PCSK9 news and video reports. |
|
For updates on hot topics,
PCSK9 news and conference reports. |
|
For the latest videos, interviews and webcasts from leading experts. |
|
|
